Eli Lilly Quintuple Agonist: Five Receptors, Greater Weight Loss Than Retatrutide

The Headline From Eli Lilly

Lilly is releasing animal study data at the American Diabetes Association Scientific Sessions in 2026 on a brand new long-acting molecule. The abstract title (Board No. 2839-LB) reads: “A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater weight loss than Retatrutide in Obese Rats.”

For people who have been tracking this category, that title is a thunderclap.

For reference, here’s the receptor evolution:

• Tirzepatide (Mounjaro, Zepbound) = GLP-1 / GIP — dual agonist
• Retatrutide = GLP-1 / GIP / glucagon — triple agonist
• The new Lilly molecule = GLP-1 / GIP / glucagon / amylin / calcitonin — quintuple

And the rat data is already showing it outperforms retatrutide, which itself produced up to 24.2% mean weight loss in 48-week phase 2 trials in humans and over 28% in the recent TRIUMPH-4 phase 3 readout.

A Little History — Coach Trevor and the First Generation

Watching this molecule announcement drop, I had a moment.

Coach Trevor and I were some of the very first people to experiment with the original generation of glp-1 agonists. Liraglutide. Saxenda. Early Ozempic. Long before they were celebrity drugs, before TikTok knew what semaglutide was, before every menopause clinic in Beverly Hills was handing out pens.

Back then we were running these compounds for fat loss in the underground bodybuilding context, and the clinical world thought we were insane. The dose ranges were tiny by today’s standards, the satiety was real but mild, and the side effect profile was rough on people who weren’t expecting it. We were already comparing them to clenbuterol cycles, T3 protocols, DNP runs, and the more aggressive sympathomimetic stacks. The honest assessment at the time: GLP-1s were impressive but not in the same league as the rapid fat loss tools we were running.

It’s wild to see how far this has come. From liraglutide doing 6-7% weight loss to a quintuple agonist hitting five receptors and outperforming everything that came before it in animal models. That’s a 15-year evolution arc most people don’t appreciate because they only entered this conversation when Ozempic became a cultural meme.

Deep Biochemistry — What Each Of The Five Receptors Actually Does

This isn’t five copies of the same lever. Each receptor activates a genuinely independent signaling pathway. That’s why stacking them works rather than producing diminishing returns.

1. GLP-1 (Glucagon-Like Peptide-1)

The backbone of the entire incretin class. GLP-1 receptor activation slows gastric emptying, suppresses appetite at the hypothalamic level, enhances glucose-dependent insulin secretion, and reduces glucagon output post-meal. This is what semaglutide, liraglutide, and exenatide all do. Strong, but on its own it tops out around 15% weight loss in humans.

2. GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP comes from K-cells of the duodenum. Adding GIP to GLP-1 was the tirzepatide breakthrough — it potentiates appetite suppression and glucose handling synergistically. Tirzepatide’s superior weight loss versus semaglutide came from this addition. Mechanism is partly central (CNS appetite circuits) and partly peripheral (insulin sensitivity).

3. Glucagon

This is the retatrutide upgrade and the most interesting receptor in the stack. Glucagon receptor activation drives energy expenditure — your body literally burns more calories at rest. This is the receptor that turns weight loss medications from “appetite suppressants” into “actual fat-burners.” Retatrutide was the first time the industry deliberately exploited this in a balanced multi-agonist. The phase 3 TRIUMPH-4 readout showed up to 28.7% body weight reduction over 68 weeks, which is the largest pharmacological weight loss ever recorded.

4. Amylin

Amylin is co-secreted with insulin from pancreatic beta-cells. The amylin receptor delivers a different flavor of satiety than GLP-1 — slower gastric emptying through a separate neural pathway, plus extended fullness that lasts longer between meals. Cagrilintide (Novo Nordisk’s amylin analog) combined with semaglutide showed weight loss data that suggested this receptor adds genuinely independent appetite suppression on top of the incretin effect.

5. Calcitonin

This one is the wild card and the most novel addition. Calcitonin receptors do three things relevant here: they extend satiety duration beyond what amylin alone provides, they improve insulin sensitivity, and they protect bone density. That last point matters — one of the legitimate concerns with rapid weight loss on glp-1 drugs is bone mineral density loss. A calcitonin component is a built-in countermeasure. Calcitonin and amylin together are sometimes called DACRA (dual amylin-calcitonin receptor agonist) class compounds.

So what you have in this molecule is: appetite suppression coming from four different angles (GLP-1, GIP, amylin, calcitonin) plus an actual metabolic accelerant (glucagon) plus bone protection. On paper this is a stack designed by someone who understood every flaw in the previous generations.

Tony Huge’s Laws of Biochemistry Physics — Law 5: Independent Receptor Stacking

This new Lilly molecule is the cleanest real-world example of Law 5 I’ve seen in a single compound.

Law 5 says: different receptors operate on independent signaling pathways. You can activate GLP-1, GIP, glucagon, amylin, and calcitonin receptors simultaneously without diminishing returns, because each one converges on the same outcome (negative energy balance and improved metabolism) through a different mechanism. Stacking compounds that hit DIFFERENT receptors is synergistic. Stacking compounds that hit the SAME receptor gives diminishing returns.

Physics analogy: batteries in parallel versus series. Five receptors in parallel give additive current without voltage competition. That’s why a quintuple agonist can plausibly outperform a triple agonist by a meaningful margin in rat models. You’re not adding more pressure to the same lever — you’re pulling five different levers that all point the same direction.

This is exactly how I think about stacking compounds in protocol design. SARMs at the androgen receptor plus GH secretagogues at the ghrelin receptor plus BPC-157 at the FAK-paxillin pathway plus a peptide bioregulator. None of them compete. All of them stack. Same principle Lilly’s medicinal chemistry team is applying at the molecular level.

But Here’s The Honest Part — These Still Aren’t As Aggressive As The Old Underground Protocols

I want to be straight about something the mainstream weight loss conversation completely misses.

Even retatrutide, with its 24-28% weight loss, is still slower and less aggressive than what Coach Trevor and I were running fifteen years ago with old-school rapid fat loss matrix protocols. The combinations we used — sympathomimetics, thyroid hormone manipulation, mitochondrial uncouplers, beta-3 selective agonists, growth hormone, SARMs to spare lean tissue, specific peptide combinations — could produce double-digit body fat percentage drops in eight to twelve weeks while maintaining or building muscle. Not body weight. Fat mass specifically.

The trade-off was that those protocols required serious knowledge, careful monitoring, and a willingness to manage real side effects. The new Lilly molecule and retatrutide and tirzepatide are vastly easier. You inject once a week. You eat less. You lose fat. You don’t need bloodwork every two weeks or ECGs or careful timing of stimulants around training. That’s the whole appeal.

So the comparison isn’t “old protocols win and new drugs lose.” The comparison is: speed and depth (old underground protocols) versus simplicity and accessibility (modern multi-agonists). Different tools for different goals.

The Ultimate Synergy — Quintuple Agonist Plus The Old Fat Loss Matrix

Here’s where it gets interesting.

The real frontier isn’t choosing between old-school rapid fat loss protocols and new multi-agonist drugs. It’s stacking them.

The Fat Loss Matrix protocol that Coach Trevor and I developed already hits multiple independent pathways: thyroid axis, sympathetic nervous system, mitochondrial efficiency, lean mass preservation via androgen support, growth hormone release, peptide-mediated fat oxidation. Adding a quintuple agonist on top would layer in five more independent receptor activations — incretin appetite control, GIP synergy, glucagon-driven energy expenditure (which doubles down on what the matrix already does sympathetically but through a completely different pathway), amylin satiety, and calcitonin bone protection.

The bone protection point is actually huge for matrix-style protocols. Aggressive fat loss protocols can hit bone density. A calcitonin component built into the weight loss drug itself is a free safety upgrade.

The math on this stack would be silly. Probably 8-12% body weight loss per month sustainably, with lean mass preserved or gained, and most of the side effects of the harder old-school compounds offset by the satiety and metabolic effects of the new molecule. I’d want to see this run in a small cohort under medical supervision before recommending broadly, but the principle is rock solid.

Natural Plus Protocol Notes

The new Lilly molecule isn’t available yet — animal data is just being presented. Phase 1 human trials would be the next step, then phase 2 dose-finding, then phase 3 registration. We’re realistically looking at 2028-2030 before this hits the market under any approved indication.

For people who want to start preparing for the multi-agonist era now:

• If you’re already on tirzepatide or retatrutide: the quintuple is going to be the natural successor. The protocol logic will transfer directly.
• If you want the underground matrix-style approach in 2026: work with someone who actually knows what they’re doing. This isn’t a YouTube protocol category. Lean mass preservation is the differentiator between a great fat loss cycle and a metabolically destructive one.
• If you want the easy modern approach: retatrutide is already the strongest available molecule. Adding amylin agonists like cagrilintide as adjuncts can approximate part of what the quintuple will do.
• Stack support compounds matter more, not less, with multi-agonists: bone density support, lean mass support via SARMs or trestolone, mitochondrial support (NAD precursors, urolithin a), and electrolyte/hydration discipline.

Stacking Recommendations

Target Audience

This article is for: people who have been around long enough to remember when GLP-1s were a niche underground topic, biohackers who want to understand where the multi-agonist class is headed before mainstream coverage catches up, athletes and physique competitors thinking about how to stack incretin drugs with traditional fat loss tools, and anyone designing protocols for sustainable rapid fat loss.

It’s not for: people looking for a celebrity-doctor explanation of “Ozempic side effects.” Plenty of those exist already.

Timeline / Expected Development Arc

Interesting Perspectives

The bone density angle is being underdiscussed. Almost every news outlet covering this is fixated on the weight loss number versus retatrutide. The calcitonin component is more strategically interesting because it directly addresses what is becoming the biggest emerging concern with the entire GLP-1 class — sarcopenia and osteopenia from rapid weight loss. Lilly designing a calcitonin component into the molecule itself is medicinal chemistry as risk management.

This is also a moat play. Compounded retatrutide is already widely available through gray-market peptide suppliers. The only way Lilly stays ahead of commoditization is to keep innovating multi-receptor molecules that the underground labs can’t easily replicate. A quintuple agonist with calcitonin built in is much harder to clone than a triple. This is Lilly running the same playbook Apple runs against Android — outpace by integration speed.

The retatrutide-to-quintuple gap will probably be smaller than the tirzepatide-to-retatrutide gap in humans. Each additional receptor delivers diminishing absolute marginal weight loss as you approach biological limits of what a body can lose without entering dangerous territory. My prediction: the quintuple shows maybe 30-32% weight loss at peak human dose, versus retatrutide’s 28%. Still meaningful, but not the leap that GLP-1 mono to triple was.

Calcitonin agonism may have implications beyond weight loss. Salmon calcitonin (the analog used in some early DACRA work) is being studied for chronic pain via descending pain modulation pathways and for migraine prophylaxis. A long-acting calcitonin agonist as part of a weight loss drug could produce off-target benefits in joint pain and headache frequency that nobody’s looking for in the trials. Watch the secondary endpoint reports.

Citations & References

FAQ

What is the Eli Lilly quintuple agonist?

It’s a long-acting investigational molecule that activates five different receptors involved in metabolism and appetite regulation: GLP-1, GIP, glucagon, amylin, and calcitonin. It’s the next step beyond retatrutide (which is a triple agonist hitting GLP-1, GIP, and glucagon). Animal study data is being presented at ADA 2026.

How does the quintuple agonist compare to retatrutide?

In early rat studies, the quintuple agonist produced greater weight loss than retatrutide. It adds amylin (extended satiety) and calcitonin (long-duration appetite control plus bone protection and insulin sensitivity) to the GLP-1/GIP/glucagon mechanism that retatrutide uses. Human data isn’t available yet, so direct comparisons in humans will take years.

Are there safety concerns with hitting five receptors at once?

Each additional receptor adds potential side effects. GLP-1 and GIP agonism produces well-documented gastrointestinal side effects. Glucagon agonism can affect heart rate and liver enzymes. Amylin and calcitonin are relatively well-tolerated. The combined profile won’t be known until phase 1 human trials, which haven’t started publicly. The calcitonin component may actually offset some safety concerns by protecting bone density during rapid weight loss.

Can you stack the quintuple agonist with other fat loss compounds?

Once it’s available, yes — and that stack will be powerful. The mechanisms involved (incretin signaling, glucagon-driven energy expenditure, satiety pathways) operate independently of androgen receptor activation, GH/IGF-1 axis modulation, thyroid manipulation, or mitochondrial uncouplers. So you can layer the quintuple on top of traditional underground rapid fat loss matrix protocols for compound effects on different pathways simultaneously. Until then, retatrutide is the strongest substitute.

Who is this molecule for?

When approved, the quintuple agonist will likely be indicated for obesity, type 2 diabetes, and possibly NAFLD/MASH and obesity-related cardiovascular disease — same indications retatrutide is being developed for. For biohackers and athletes, it’ll be the most aggressive single-injection fat loss tool available with a relatively manageable side effect profile.

Tony Huge has been working with peptides, multi-agonists, and underground rapid fat loss protocols since the original generation of GLP-1 receptor agonists hit the market. Coach Trevor and tony huge co-developed the original Fat Loss Matrix protocol that combined sympathomimetics, thyroid hormone manipulation, mitochondrial uncouplers, growth hormone, sarms for lean mass preservation, and targeted peptides — a protocol still cited as one of the most effective rapid fat loss systems ever documented in the underground research community.